Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,824 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma.
Tookman L, Rashid S, Matakidou A, Phillips M, Wilson P, Ansell W, Jamal-Hanjani M, Chowdhury S, Harland S, Sarwar N, Oliver T, Powles T, Shamash J. Tookman L, et al. Among authors: phillips m. Acta Oncol. 2013 Jun;52(5):987-93. doi: 10.3109/0284186X.2012.714078. Epub 2012 Sep 3. Acta Oncol. 2013. PMID: 22943385
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A. Szlosarek PW, et al. Among authors: phillips mm. JAMA Oncol. 2017 Jan 1;3(1):58-66. doi: 10.1001/jamaoncol.2016.3049. JAMA Oncol. 2017. PMID: 27584578 Clinical Trial.
Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek PW, Shamash J, Rashid S. Crusz SM, et al. Among authors: phillips m. Eur J Cancer. 2018 Oct;102:49-51. doi: 10.1016/j.ejca.2018.07.125. Epub 2018 Aug 20. Eur J Cancer. 2018. PMID: 30138772 No abstract available.
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Szlosarek PW, Wimalasingham AG, Phillips MM, Hall PE, Chan PY, Conibear J, Lim L, Rashid S, Steele J, Wells P, Shiu CF, Kuo CL, Feng X, Johnston A, Bomalaski J, Ellis S, Grantham M, Sheaff M. Szlosarek PW, et al. Among authors: phillips mm. Cancer Med. 2021 Oct;10(19):6642-6652. doi: 10.1002/cam4.4196. Epub 2021 Aug 12. Cancer Med. 2021. PMID: 34382365 Free PMC article. Clinical Trial.
Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms.
Szlosarek PW, Phillips MM, Pavlyk I, Steele J, Shamash J, Spicer J, Kumar S, Pacey S, Feng X, Johnston A, Bomalaski J, Moir G, Lau K, Ellis S, Sheaff M. Szlosarek PW, et al. Among authors: phillips mm. JTO Clin Res Rep. 2020 Sep 3;1(4):100093. doi: 10.1016/j.jtocrr.2020.100093. eCollection 2020 Nov. JTO Clin Res Rep. 2020. PMID: 34589965 Free PMC article.
A Phase 1 study of ADI-PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1-negative metastatic uveal melanoma.
Chan PY, Phillips MM, Ellis S, Johnston A, Feng X, Arora A, Hay G, Cohen VML, Sagoo MS, Bomalaski JS, Sheaff MT, Szlosarek PW. Chan PY, et al. Among authors: phillips mm. Pigment Cell Melanoma Res. 2022 Jul;35(4):461-470. doi: 10.1111/pcmr.13042. Epub 2022 May 16. Pigment Cell Melanoma Res. 2022. PMID: 35466524 Free PMC article. Clinical Trial.
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Pharmacol Rep. 2023 Jun;75(3):753. doi: 10.1007/s43440-023-00487-z. Pharmacol Rep. 2023. PMID: 37195562 Free PMC article. No abstract available.
Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.
Szyszko TA, Dunn JT, Phillips MM, Bomalaski J, Sheaff MT, Ellis S, Pike L, Goh V, Cook GJR, Szlosarek PW. Szyszko TA, et al. Among authors: phillips mm. JTO Clin Res Rep. 2022 Jul 20;3(9):100382. doi: 10.1016/j.jtocrr.2022.100382. eCollection 2022 Sep. JTO Clin Res Rep. 2022. PMID: 36082278 Free PMC article.
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Pharmacol Rep. 2023 Jun;75(3):570-584. doi: 10.1007/s43440-023-00480-6. Epub 2023 Apr 3. Pharmacol Rep. 2023. PMID: 37010783 Free PMC article.
4,824 results